Search Results 1221-1230 of 16272 for monoclonal antibody

  1. A Study to Evaluate Entolimod on Immune System Aging in Healthy Geriatric Subjects Receiving Influenza Vaccination - Mayo Clinic

    The purpose of this study is to measure changes of the anti- A/H1N1, anti-A/H3N2, and anti-B influenza virus strains serum circulating antibodies (as assessed ...

  2. A Study of the Safety and Effectiveness of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unremoveable Malignant Pleural Mesothelioma - Mayo Clinic

    ... monoclonal antibody therapy, amatuximab or any of its excipients); Pregnant and/or lactating females are excluded. A negative beta-human chorionic ...

  3. A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM - Mayo Clinic

    Chemotherapy, biologic therapy (i.e., small molecular inhibitors), monoclonal antibodies ... antibody on a shorter frequency (i.e., every two weeks), then the ...

  4. Publications - Sean J. Pittock, M.D. - Mayo Clinic

    B cell and aquaporin-4 antibody relationships with neuromyelitis optica spectrum disorder activity. Ann Clin Transl Neurol. 2024 Oct; 11(10):2792-2798. Epub ...

  5. A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy - Mayo Clinic

    Known hypersensitivity to another monoclonal antibody that cannot be controlled with standard measures (e.g., antihistamines and corticosteroids) or known ...

  6. A Study to Extend a Previous Trial of Eculizumab in Patients with Relapsing Neuromyelitis Optica - Mayo Clinic

    Complement activation after binding of an IgG autoantibody ... monoclonal IgG that neutralises the complement protein C5--in neuromyelitis optica spectrum ...

  7. Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma - Mayo Clinic

    Patients who have received any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) ≤ 5 effective half-lives prior to ...

  8. A Study to Evaluate Intravenous Erenumab in Patients with Status Migrainosus - Mayo Clinic

    Past (within 4 months) or present exposure to a CGRP monoclonal antibody or CGRP small molecule receptor antagonist for migraine treatment. Present exposure ...

  9. Publications

    Risk of Incident Melanoma Among Individuals With Low-Count Monoclonal B-Cell Lymphocytosis. J Clin Oncol. 2024 Dec 10; 42 (35):4153-4162 Epub 2024 Sept 04

  10. A Phase 2, Multicenter, Randomized Study of AP26113 - Mayo Clinic

    Received monoclonal antibodies or had major surgery within 30 days of the first dose of AP26113 (Day 1, Cycle 1). Have been diagnosed with another primary ...